Activities
ATONCO SAS
"Astatine against cancer"
Atonco is a clinical-stage radiopharmaceutical company developing innovative radiopharmaceuticals using astatine-211, an alpha emitting radionuclide for the treatment of cancer. Atonco, founded in 2019 and built with an experienced and passionate team, has exclusive worldwide licenses for the use of an antibody and innovative proprietary radiolabeling technology.
Atonco, based on a disruptive and innovative alpha-immunotherapy, addresses two objectives:
– clinical indications with real unmet therapeutic needs
– rapidly accessible tumor targets, adapted to the short half-life of astatine-211 (7.2h) and whose small size is adapted to the very short path length of the emitted alpha particles.
